Silabe

Executive Summary

Silabe, based in Strasbourg, France, is a non-human primate (NHP) research platform operated by the University of Strasbourg. Founded in 1990, Silabe offers a wide range of services to the scientific community, including NHP models for fundamental and applied research, as well as professional training programs. The platform supports academic and industrial researchers by providing access to specialized primate models, which are critical for preclinical studies in fields such as neuroscience, infectious diseases, and biologics development. Silabe also hosts students and professionals seeking hands-on experience in primate research, contributing to the next generation of scientists. As a university-affiliated facility, Silabe benefits from strong institutional support and a reputation for quality and ethical standards in animal research. Looking ahead, Silabe is well-positioned to capitalize on the growing demand for NHP models in drug development, particularly for biologics and antibody-based therapies. However, as a service platform rather than a drug developer, its growth is tied to research funding and collaboration trends. The company's conviction score is moderate, reflecting its stable but niche market position. Key upcoming catalysts include potential expansion of its facility to accommodate larger studies, new training partnerships with pharmaceutical companies, and the launch of advanced imaging or behavioral analysis services. These initiatives could enhance Silabe's competitiveness and revenue streams, though success depends on securing funding and regulatory approvals.

Upcoming Catalysts (preview)

• Q4 2026Facility expansion to increase NHP housing capacity70% success
• Q2 2027Strategic partnership with a major pharma for preclinical services50% success
• Q3 2026Launch of new behavioral neuroscience service line60% success